Vitamin D as a T-cell Modulator in Multiple Sclerosis

Vitamins and Hormones

Volumn 86, Issue , 2011, Pages 401-428

  Smolders, Joost ^a   Damoiseaux, Jan ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

1,25 Dihydroxyvitamin D; 25 Hydroxyvitamin D; Autoimmune diseases; B lymphocyte; Dendritic cell; Immune regulation; Multiple sclerosis; Regulatory T lymphocyte; T lymphocyte; Vitamin D

Indexed keywords

VITAMIN D;

ANIMAL; BOOK; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNOMODULATION; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; VITAMIN D;

EID: 79952661796     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386960-9.00018-6     Document Type: Book

References (115)

1. Abbas S., Linseisen J., Slanger T., Kropp S., Mutschelknauss E.J., Flesch-Janys D., Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer: Results of a large case-control study. Carcinogenesis 2008, 29:93-99.
2. Ascherio A., Munger K.L., Simon C. Vitamin D and multiple sclerosis. Lancet Neurol. 2010, 9:599-612.
3. Balashov K.E., Olek M.J., Smith D.R., Khoury S.J., Weiner H.L. Seasonal variation of interferon-gamma production in progressive multiple sclerosis. Ann. Neurol. 1998, 44:824-828.
4. Bar-Or A. The immunology of multiple sclerosis. Semin. Neurol. 2008, 28:29-45.
5. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., de Waal-Malefyt R., Coffman R.L., Hawrylowicz C.M., O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 2002, 195:603-616.
6. Bates C.J., Carter G.D., Mishra G.D., O'Shea D., Jones J., Prentice A. In a population study, can parathyroid hormone aid the definition of adequate vitamin D status? A study of people aged 65 years and over from the British National Diet and Nutrition Survey. Osteoporos. Int. 2003, 14:152-159.
7. Becklund B.R., Hansen D.W., Deluca H.F. Enhancement of 1, 25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin. Proc. Natl. Acad. Sci. USA 2009, 106:5276-5281.
8. Bhalla A.K., Amento E.P., Krane S.M. Differential effects of 1, 25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: Inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell. Immunol. 1986, 98:311-322.
9. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: A population-based study of younger and older adults. Am. J. Med. 2004, 116:634-639.
10. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Giovannucci E., Dietrich T., Dawson-Hughes B. Fracture prevention with vitamin D supplementation, a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257-2264.
11. Bischoff-Ferrari H.A., Dawson-Hughes B., Orav J.E., Stuck A.E., Theiler R., Wong J.B., Egli A., Kiel D.P., Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: A meta-analysis of randomized controlled trials. BMJ 2009, 339:b3692.
12. Boonstra A., Barrat F.J., Crain C., Heath V.L., Savelkoul H.F., O'Garra A. 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 2001, 167:4974-4980.
13. Cantorna M.T., Hayes C.E., DeLuca H.F. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 1996, 93:7861-7864.
14. Cantorna M.T., Humpal-Winter J., DeLuca H.F. Dietary calcium is a major factor in 1, 25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J. Nutr. 1999, 129:1966-1971.
15. Cauley J.A., Parimi N., Ensrud K.E., Bauer D.C., Cawthon P.M., Cummings S.R., Hoffman E.R., Shikany J.M., Barrett-Connor E., Orwoll E. Serum 25 hydroxyvitamin D and the risk of hip and non-spine fractures in older men. J. Bone Min. Res. 2009, 25:545-553.
16. Chen W.C., Vayuvegula B., Gupta S. 1, 25-Dihydroxyvitamin D3-mediated inhibition of human B cell differentiation. Clin. Exp. Immunol. 1987, 69:639-646.
17. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
18. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
19. Correale J., Ysrraelit M.C., Gaitán M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132:1146-1160.
20. Cutolo M., Otsa K., Laas K., Yprus M., Lehtme R., Secchi M.E., Sulli A., Paolino S., Seriolo B. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin. Exp. Rheumatol. 2006, 24:702-704.
21. D'Ambrosio D., Cippitelli M., Cocciolo M.G., Mazzeo D., Di Lucia P., Lang R., Sinigaglia F., Panina-Bordignon P. Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J. Clin. Invest. 1998, 101:252-262.
22. Davies P.S., Bates C.J., Cole T.J., Prentice A., Clarke P.C. Vitamin D: Seasonal and regional differences in preschool children in Great Britain. Eur. J. Clin. Nutr. 1999, 53:195-198.
23. de Andres C., Aristimuno C., de Las Heras V., Martinez-Gines M.L., Bartolome M., Arroyo R., et al. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 2007, 182:204-211.
24. Eikelenboom M.J., Killestein J., Kragt J.J., Uitdehaag B.M., Polman C.H. Gender differences in multiple sclerosis: Cytokines and vitamin D. J. Neurol. Sci. 2009, 286:40-42.
25. Fritsche J., Mondal K., Ehrnsperger A., Andreesen R., Kreutz M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003, 102:3314-3316.
26. Gatenby P.A., Lucas R.M., Engelsen O., Ponsonby A.L., Clements M. Antineutrophil cytoplasmic antibody-associated vasculitides: Could geographic patterns be explained by ambient ultraviolet radiation?. Arthritis Rheum. 2009, 61:1417-1424.
27. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-Hydroxyvitamin D and risk of myocardial infarction in men A prospective study. Arch. Intern. Med. 2008, 168:1174-1180.
28. Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB J. 2005, 19:1067-1077.
29. Gottfried E., Rehli M., Hahn J., Holler E., Andreesen R., Kreutz M. Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. Biochem. Biophys. Res. Commun. 2006, 349:209-213.
30. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
31. Griffin M.D., Lutz W.H., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem. Biophys. Res. Commun. 2000, 270:701-708.
32. Griffin M.D., Lutz W., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98:6800-6805.
33. high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 2005, 35:3343-3352.
34. Hayes C.E., Cantorna M.T., DeLuca H.F. Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 1997, 216:21-27.
35. Heine G., Niesner U., Chang H.D., Steinmeyer A., Zügel U., Zuberbier T., Radbruch A., Worm M. 1, 25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur. J. Immunol. 2008, 38:2210-2218.
36. 3 and 25-hydroxyvitamin D in humans: An important tool to define adequate nutritional vitamin D status. J. Steroid Biochem. Mol. Biol. 2007, 103:631-634.
37. Hyppönen E., Läärä E., Reunanen A., Järvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 2001, 358:1500-1503.
38. Iho S., Takahashi T., Kura F., Sugiyama H., Hoshino T. The effect of 1, 25-dihydroxyvitamin D3 on in vitro immunoglobulin production in human B cells. J. Immunol. 1986, 136:4427-4431.
39. Islam T., Gauderman W., Cozen W., Mack T. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007, 69:381-388.
40. Jeffery L.E., Burke F., Mura M., Zheng Y., Qureshi O.S., Hewison M., Walker L.S., Lammas D.A., Raza K., Sansom D.M. 1, 25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 2009, 183:5458-5467.
41. Jongen M.J.M., van der Vijgh W.J.F., Lips P., Netelenbos J.C. Measurement of vitamin D metabolites in anephric subjects. Nephron 1984, 36:230-234.
42. Kampman M., Wilsgaard T., Mellgren S. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic circle. J. Neurol. 2007, 254:471-477.
43. Killestein J., Rep M.H., Meilof J.F., Ader H.J., Uitdehaag B.M., Barkhof F., van Lier R.A., Polman C.H. Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 2002, 58:1077-1080.
44. Kimball S.M., Ursell M.R., O'Connor P., Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 2007, 86:645-651.
45. Kimlin M.G. Geographical location and vitamin D synthesis. Mol. Aspects Med. 2008, 29:453-461.
46. Lemire J.M., Archer D.C. 1, 25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 1991, 87:1103-1107.
47. Lemire J.M., Adams J.S., Sakai R., Jordan S.C. 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J. Clin. Invest. 1984, 74:657-661.
48. Lopes J., Danilevicius C., Takayama L., Caparbo V., Scazufca M., Bonfá E., Pereira R. Vitamin D insufficiency: A risk factor to vertebral fractures in community-dwelling elderly women. Maturitas 2009, 64:218-222.
49. Mahon B.D., Gordon S.A., Cruz J., Cosman F., Cantorna M.T. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 2003, 134:128-132.
50. 3 and its polar metabolites in human serum. Nature 1969, 222:482-483.
51. Meehan T.F., DeLuca H.F. CD8(+) T cells are not necessary for 1alpha, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Proc. Natl. Acad. Sci. USA 2002, 99:5557-5560.
52. Meehan T.F., DeLuca H.F. The vitamin D receptor is necessary for 1alpha, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch. Biochem. Biophys. 2002, 408:200-204.
53. Meehan M.A., Kerman R.H., Lemire J.M. 1, 25-Dihydroxyvitamin D3 enhances the generation of nonspecific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell. Immunol. 1992, 140:400-409.
54. Melamed M.L., Michos E.D., Post W., Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 2008, 168:1629-1637.
55. Melamed M.L., Muntner P., Michos E.D., Uribarri J., Weber C., Sharma J., Raggi P. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1179-1185.
56. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348:15-23.
57. Mowry E.M., Krupp L.B., Milazzo M., Chabas D., Strober J.B., Belman A.L., et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann. Neurol. 2010, 67:618-624.
58. - cells. Autoimmunity 1992, 14:37-43.
59. Müller K., Heilmann C., Poulsen L.K., Barington T., Bendtzen K. The role of monocytes and T cells in 1, 25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. Immunopharmacology 1991, 21:121-128.
60. Müller K., Diamant M., Bendtzen K. Inhibition of production and function of interleukin-6 by 1, 25-dihydroxyvitamin D3. Immunol. Lett. 1991, 28:115-120.
61. Müller K., Haahr P.M., Diamant M., Rieneck K., Kharazmi A., Bendtzen K. 1, 25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992, 4:506-512.
62. Müller K., Kriegbaum N.J., Baslund B., Sørensen O.H., Thymann M., Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: Low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin. Rheumatol. 1995, 14:397-400.
63. Munger K.L., Zhang S.M., O'Reilly E., Hernán M.A., Olek M.J., Willett W.C., Ascherio A. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
64. Munger K., Levin L., Hollis B., Howard N., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
65. Muthian G., Raikwar H.P., Rajasingh J., Bright J.J. 1, 25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J. Neurosci. Res. 2006, 83:1299-1309.
66. Nashold F.E., Hoag K.A., Goverman J., Hayes C.E. Rag-1-dependent cells are necessary for 1, 25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2001, 119:16-29.
67. Neuhaus O., Wiendl H., Kieseier B.C., Archelos J.J., Hemmer B., Stuve O., et al. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J. Neuroimmunol. 2005, 168:128-137.
68. Newton-Bishop J.A., Beswick S., Randerson-Moor J., Chang Y.M., Affleck P., Elliott F., Chan M., Leake S., Karpavicius B., Haynes S., Kukalizch K., Whitaker L., et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J. Clin. Oncol. 2009, 27:5439-5444.
69. Nordvik I., Myhr K.M., Nyland H., Bjerve K.S. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol. Scand. 2000, 102:143-149.
70. Ohta M., Okabe T., Ozawa K., Urabe A., Takaku F. 1 alpha, 25-Dihydroxyvitamin D3 (calcitriol) stimulates proliferation of human circulating monocytes in vitro. FEBS Lett. 1985, 185:9-13.
71. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., Eber G.C. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol. 2006, 5:932-936.
72. Penna G., Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000, 164:2405-2411.
73. Penna G., Amuchastegui S., Giarratana N., Daniel K.C., Vulcano M., Sozzani S., Adorini L. 1, 25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol. 2007, 178:145-153.
74. Pichler J., Gerstmayr M., Szépfalusi Z., Urbanek R., Peterlik M., Willheim M. 1 alpha, 25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Pediatr. Res. 2002, 52:12-18.
75. Piemonti L., Monti P., Sironi M., Fraticelli P., Leone B.E., Dal Cin E., Allavena P., Di Carlo V. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 2000, 164:4443-4451.
76. Pilz S., Dobnig H., Nijpels G., Heine R.J., Stehouwer C.D., Snijder M.B., van Dam R.M., Dekker J.M. Vitamin D and mortality in older men and women. Clin. Endocrinol. (Oxf) 2009, 71:666-672.
77. Pilz S., Tomaschitz A., Ritz E., Pieber T.R. Vitamin D status arterial hypertension: A systematic review. Nat. Rev. Cardiol. 2009, 6:621-630.
78. Provvedini D.M., Tsoukas C.D., Deftos L.J., Manolagas S.C. 1, 25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 1983, 221:1181-1183.
79. Reichel H., Koeffler H.P., Tobler A., Norman A.W. 1 alpha, 25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 1987, 84:3385-3389.
80. Rigby W.F., Stacy T., Fanger M.W. Inhibition of T lymphocyte mitogenesis by 1, 25-dihydroxyvitamin D3 (calcitriol). J. Clin. Invest. 1984, 74:1451-1455.
81. Rigby W.F., Waugh M., Graziano R.F. Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1, 25-dihydroxyvitamin D3. Blood 1990, 76:189-197.
82. Royal W., Mia Y., Li H., Naunton K. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J. Neuroimmunol. 2009, 213:135-141.
83. Schrempf W., Ziemssen T. Glatiramer acetate: Mechanisms of action in multiple sclerosis. Autoimmun. Rev. 2007, 6:469-475.
84. Shiozawa S., Shiozawa K., Tanaka Y., Fujita T. 1 alpha, 25-Dihydroxyvitamin D3 inhibits proliferative response of T- and B lymphocytes in a serum-free culture. Int. J. Immunopharmacol. 1987, 9:719-723.
85. Sigmundsdottir H., Pan J., Debes G.F., Alt C., Habtezion A., Soler D., Butcher E.C. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 2007, 8:285-293.
86. Simpson S., Taylor B., Blizzard L., Ponsonby A.L., Pittas F., Tremlett H., et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Ann. Neurol. 2010, 68:193-203.
87. Smith J.E., Goodman D.S. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J. Clin. Invest. 1971, 50:2159-2167.
88. Smolders J., Damoiseaux J., Menheere P., Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 2008, 194:7-17.
89. Smolders J., Menheere P., Kessels A., Damoiseaux J., Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 2008, 14:1220-1224.
90. Smolders J., Peelen E., Thewissen M., Menheere P., Cohen Tervaert J.W., Hupperts R., Damoiseaux J. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun. Rev. 2009, 8:621-626.
91. Smolders J., Thewissen M., Peelen E., Menheere P., Cohen Tervaert J.W., Damoiseaux J., Hupperts R. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS ONE 2009, 4:e6635.
92. Smolders J., Menheere P., Thewissen M., Peelen E., Cohen Tervaert J.W., Hupperts R., Damoiseaux J. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1, 25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J. Steroid Biochem. Mol. Biol. 2010, 121:243-246.
93. Soilu-Hänninen M., Laaksonen M., Laitinen I., Eralinna J.P., Lilius E.M., Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact PTH levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2008, 79:152-157.
94. Soilu-Hänninen M., Airas L., Mononen I., Heikkilä A., Viljanen M., Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 2005, 11:266-271.
95. Sørensen T.L., Trebst C., Kivisäkk P., Klaege K.L., Majmudar A., Ravid R., Lassmann H., Olsen D.B., Strieter R.M., Ransohoff R.M., Sellebjerg F. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J. Neuroimmunol. 2002, 127:59-68.
96. Spach K.M., Hayes C.E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 2005, 175:4119-4126.
97. Spach K.M., Nashold F.E., Dittel B.N., Hayes C.E. IL-10 signaling is essential for 1, 25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:6030-6037.
98. Stewart N., Taylor B., Ponsonby A.L., Pittas F., van der Mei I., Woods G., Walters H. The effect of season on cytokine expression in multiple sclerosis and healthy subjects. J. Neuroimmunol. 2007, 188:181-186.
99. Stewart J.W., Alekel D.L., Ritland L.M., Van Loan M., Gertz E., Genschel U. Serum 25-hydroxyvitamin D is related to indicators of overall physical fitness in healthy postmenopausal women. Menopause 2009, 16:1093-1101.
100. Széles L., Keresztes G., Töröcsik D., Balajthy Z., Krenács L., Póliska S., Steinmeyer A., Zuegel U., Pruenster M., Rot A., Nagy L. 1, 25-Dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J. Immunol. 2009, 182:2074-2083.
101. Tang B., Eslick G., Nowson C., Smith C., Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007, 370:657-666.
102. Tang J.Y., Parimi N., Wu A., John Boscardin W., Shikany J.M., Chren M.M., Cummings S.R., Epstein E.H., Bauer D.C. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 2010, 21:387-391.
103. Thien R., Baier K., Pietschmann P., Peterlik M., Willheim M. Interactions of 1 alpha, 25-dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes. J. Allergy Clin. Immunol. 2005, 116:683-689.
104. Tobler A., Gasson J., Reichel H., Norman A.W., Koeffler H.P. Granulocyte-macrophage colony-stimulating factor. Sensitive and receptor-mediated regulation by 1, 25-dihydroxyvitamin D3 in normal human peripheral blood lymphocytes. J. Clin. Invest. 1987, 79:1700-1705.
105. Van der Mei I., Ponsonby A., Dwyer T., Blizzard L., Taylor B.V., Kilpatrick T., Butzkueven H., McMichael A.J. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 2007, 254:581-590.
106. Van Etten E., Branisteanu D.D., Overbergh L., Bouillon R., Verstuyf A., Mathieu C. Combination of a 1, 25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 2003, 32:397-404.
107. van Halteren A.G., van Etten E., de Jong E.C., Bouillon R., Roep B.O., Mathieu C. Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1, 25 dihydroxyvitamin D(3). Diabetes 2002, 51:2119-2125.
108. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1, 25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374:334-338.
109. + regulatory T-cell function and FOXP3 expression. J. Neurosci. Res. 2006, 83:1432-1446.
110. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
111. Von Essen M.R., Kongsbak M., Schjerling P., Olgaard K., Ødum N., Geisler C. Vitamin D controls T cell receptor signaling and activation of human T cells. Nat. Immunol. 2010, 11:344-349.
112. Willer C.J., Dyment D.A., Sadovnick A.D., Rothwell P.M., Murray T.J., Ebers G.C. Timing of birth and risk of multiple sclerosis: Population based study. BMJ 2005, 330:120.
113. Wingerchuk D.M., Lesaux J., Rice G.P., Kremenchutzky M., Ebers G.C. A pilot study of oral calcitriol (1, 25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2005, 76:1294-1296.
114. Yin L., Grandi N., Raum E., Haug U., Arndt V., Brenner H. Meta-analysis: Longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment. Pharmacol. Ther. 2009, 13:113-125.
115. Yin L., Raum E., Haug U., Arndt V., Brenner H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009, 33:435-445.